Chugai Pharmaceutical Co., Ltd. (4519) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Chugai Pharmaceutical Co., Ltd. (4519:JPX), powered by AI.

Current Price
¥7,428
P/E Ratio
28.2
Market Cap
12.2T
Sector
Healthcare
What is the Chugai Pharmaceutical Co., Ltd. stock price forecast?

Chugai Pharmaceutical Co., Ltd. is currently trading at ¥7,428. View real-time AI analysis on Alpha Lenz.

What is Chugai Pharmaceutical Co., Ltd. insider trading activity?

View the latest insider trading data for Chugai Pharmaceutical Co., Ltd. on Alpha Lenz.

What is Chugai Pharmaceutical Co., Ltd.'s P/E ratio?

Chugai Pharmaceutical Co., Ltd.'s P/E ratio is 28.2.

Chugai Pharmaceutical Co., Ltd.

JPX · 4519
¥7,428-22(-0.30%)Market closedJPX regular session 09:00–15:00 JST
Ask about Chugai Pharmaceutical Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Chugai Pharmaceutical Co., Ltd. trades at a P/E of 28.2 (premium valuation) with strong ROE of 22.1%. Operating margin of 47.6% indicates strong profitability.

Ask for details

Company Overview

Chugai Pharmaceutical Co., Ltd. is a prominent pharmaceutical company involved in research, development, manufacturing, and marketing of a wide range of pharmaceutical products. Its primary aim is to advance the field of medicine by focusing on the development of innovative therapies that address unmet medical needs. Chugai operates primarily in the fields of oncology, renal disease, and bone and joint diseases, leveraging its capabilities in biotechnology antibody pharmaceuticals. Notably, the company collaborates closely with Roche Group, enabling it to leverage advanced science and technology in drug discovery and development. Chugai's influence is significant in both Japanese and global markets, as it continues to contribute to the enhancement of healthcare by providing high-quality pharmaceutical solutions. Founded in 1925, Chugai is strongly committed to its mission of providing valuable products and services that align with the needs of patients and healthcare providers worldwide.

CEODr. Osamu Okuda
SectorHealthcare
IndustryDrug Manufacturers - General
Employees5,026

Company Statistics

FY 2025

Profile

¥12,223,974,468,792Market Cap
¥1,257,941,000,000Revenue
0.00Shares Out
5,026Employees

Margins

71.09%Gross
47.54%EBITDA
47.60%Operating
47.52%Pre-Tax
34.50%Net

Valuation

28.17P/E
6.03P/B
9.72EV/Sales
19.73EV/EBITDA
44.50P/FCF

Growth (CAGR)

-0.05%Rev 3Yr
9.84%Rev 5Yr
3.94%Op Inc 3Yr
14.73%Op Inc 5Yr
5.05%Net Inc 3Yr
15.11%Net Inc 5Yr

Returns

18.56%ROA
22.10%ROE
25.57%ROIC

Financial Health

¥426,602,000,000Cash & Cash Equivalents
¥16,261,000,000Net Debt
21.86%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Chugai Pharmaceutical Co., Ltd. (ticker: 4519) is a company listed on JPX in the Healthcare sector (Drug Manufacturers - General). It has approximately 5,026 employees. Market cap is $12.2T.

The current price is 7,428 with a P/E ratio of 28.17x and P/B of 6.03x.

ROE is 22.10% and operating margin is 47.60%. Annual revenue is $1.3T.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Chugai Pharmaceutical Co., Ltd. (4519) Stock Forecast 2026 ¥7,428 — Price, Financials & Analyst Targets | Alpha Lenz